Literature DB >> 30872269

CDK9 and mTOR: trading places.

Katherine L B Borden1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30872269      PMCID： PMC6418479          DOI： 10.1182/blood-2019-01-895086

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Eukaryotic mRNPs may represent posttranscriptional operons.

Authors:  Jack D Keene; Scott A Tenenbaum
Journal:  Mol Cell       Date:  2002-06       Impact factor: 17.970

2.  A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.

Authors:  David A Rizzieri; Eric Feldman; John F Dipersio; Nashat Gabrail; Wendy Stock; Roger Strair; Victor M Rivera; Maher Albitar; Camille L Bedrosian; Francis J Giles
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

3.  mTOR Signaling in Growth, Metabolism, and Disease.

Authors:  Robert A Saxton; David M Sabatini
Journal:  Cell       Date:  2017-04-06       Impact factor: 41.582

4.  Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1.

Authors:  David A Guertin; Deanna M Stevens; Carson C Thoreen; Aurora A Burds; Nada Y Kalaany; Jason Moffat; Michael Brown; Kevin J Fitzgerald; David M Sabatini
Journal:  Dev Cell       Date:  2006-12       Impact factor: 12.270

Review 5.  Targeting the mTOR Pathway in Leukemia.

Authors:  Shira Dinner; Leonidas C Platanias
Journal:  J Cell Biochem       Date:  2016-04-06       Impact factor: 4.429

Review 6.  Regulatory Potential of the RNA Processing Machinery: Implications for Human Disease.

Authors:  Kirstyn T Carey; Vihandha O Wickramasinghe
Journal:  Trends Genet       Date:  2018-01-09       Impact factor: 11.639

Review 7.  Aiding and abetting cancer: mRNA export and the nuclear pore.

Authors:  Biljana Culjkovic-Kraljacic; Katherine L B Borden
Journal:  Trends Cell Biol       Date:  2013-04-10       Impact factor: 20.808

8.  Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.

Authors:  Sarit Assouline; Biljana Culjkovic; Eftihia Cocolakis; Caroline Rousseau; Nathalie Beslu; Abdellatif Amri; Stephen Caplan; Brian Leber; Denis-Claude Roy; Wilson H Miller; Katherine L B Borden
Journal:  Blood       Date:  2009-05-11       Impact factor: 22.113

9.  Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.

Authors:  Elspeth M Beauchamp; Sameem M Abedin; Sara G Radecki; Mariafausta Fischietti; Ahmet Dirim Arslan; Gavin T Blyth; Angela Yang; Connor Lantz; Alissa Nelson; Young Ah Goo; Imo Akpan; Elizabeth A Eklund; Olga Frankfurt; Eleanor N Fish; Paul M Thomas; Jessica K Altman; Leonidas C Platanias
Journal:  Blood       Date:  2018-12-26       Impact factor: 22.113

Review 10.  Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.

Authors:  Vladimír Krystof; Sonja Baumli; Robert Fürst
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116
  10 in total
  1 in total

Review 1.  Targeting cyclin-dependent kinase 9 in cancer therapy.

Authors:  Yi-Li Shen; Yan-Mao Wang; Ya-Xin Zhang; Shen-Jie Ma; Le-He Yang; Cheng-Guang Zhao; Xiao-Ying Huang
Journal:  Acta Pharmacol Sin       Date:  2021-11-22       Impact factor: 7.169
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.